Prognostic Role of PD-L1 Expression in Invasive Breast Cancer: A Systematic Review and Meta-Analysis

被引:17
|
作者
Cirqueira, Magno Belem [1 ]
Mendonca, Carolina Rodrigues [1 ]
Noll, Matias [1 ,2 ,3 ]
Soares, Leonardo Ribeiro [4 ]
de Paula Carneiro Cysneiros, Maria Auxiliadora [1 ]
Paulinelli, Regis Resende [3 ]
Moreira, Marise Amaral Reboucas [1 ]
Freitas-Junior, Ruffo [4 ]
机构
[1] Univ Fed Goias, Postgrad Program Hlth Sci, BR-74605050 Goiania, Go, Brazil
[2] Inst Fed Goiano Goiano, BR-74270040 Goiania, Go, Brazil
[3] Univ Southern Denmark, Dept Sports Sci & Clin Biomech, DK-5230 Odense, Denmark
[4] Univ Fed Goias UFG, Univ Hosp, Dept Obstet & Gynecol, Mastol Program, BR-74605050 Goiania, Go, Brazil
关键词
breast cancer; PD-L1; prognosis; immunohistochemistry; TUMOR-INFILTRATING LYMPHOCYTES; LIGAND; EXPRESSION; CARCINOMA; MARKER; CELLS;
D O I
10.3390/cancers13236090
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The role of PD-L1 expression in breast cancer remains controversial. Therefore, we performed a systematic review and meta-analysis to assess the association of PD-L1 expression with clinicopathological variables, overall survival (OS), and disease-free survival (DFS) in invasive breast cancer. PD-L1 expression was associated with age >= 50 years, lymph node status-negative, progesterone receptor-negative, Ki67 >= 20%, and human epidermal growth factor receptor 2 (HER2)-negative. PD-L1 positivity was associated with worse OS; however, there was no significant improvement in DFS. PD-L1 positivity was significantly associated with the clinicopathological characteristics of favorable and unfavorable prognoses. However, the final clinical outcome was associated with lower OS and had no significant association with DFS. Programmed death ligand 1 (PD-L1) has been investigated in various types of cancer; however, the role of PD-L1 expression in breast cancer remains controversial. We performed a systematic review and meta-analysis to assess the association of PD-L1 expression with clinicopathological variables, overall survival (OS), and disease-free survival (DFS) in invasive breast cancer. A total of 965 articles were included from CINAHL, Embase, PubMed, and Scopus databases. Of these, 22 studies encompassing 6468 cases of invasive breast cancer were included in the systematic review, and 15 articles were included in the meta-analysis. PD-L1 expression was associated with age >= 50 years, lymph node status-negative, progesterone receptor-negative, Ki67 >= 20%, and human epidermal growth factor receptor 2 (HER2)-negative. PD-L1 positivity was associated with worse OS (hazard ratio, HR, 2.39; 95% confidence interval, CI, 1.26-3.52; p =< 0.000); however, there was no significant improvement in DFS (HR 0.17; 95% CI -0.12-0.46; p =< 0.252). PD-L1 positivity was significantly associated with the clinicopathological characteristics of favorable and unfavorable prognoses. However, the final clinical outcome was associated with lower OS and had no significant association with DFS.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
    Elisabeth Specht Stovgaard
    Anne Dyhl-Polk
    Anne Roslind
    Eva Balslev
    Dorte Nielsen
    Breast Cancer Research and Treatment, 2019, 174 : 571 - 584
  • [22] PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis
    Hao, Chengcheng
    Chen, Gang
    Zhao, Huishan
    Li, Yan
    Chen, Jianxin
    Zhang, Hongmei
    Li, Shan
    Zhao, Yuze
    Chen, Feng
    Li, Wenbin
    Jiang, Wen G.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
    Áurea Lima
    Hugo Sousa
    Rui Medeiros
    Amanda Nobre
    Manuela Machado
    Discover Oncology, 13
  • [24] PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
    Lima, Aurea
    Sousa, Hugo
    Medeiros, Rui
    Nobre, Amanda
    Machado, Manuela
    DISCOVER ONCOLOGY, 2022, 13 (01)
  • [25] Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis
    Fu, Hanlin
    Fu, Zhihui
    Mao, Meng
    Si, Lulu
    Bai, Jing
    Wang, Qian
    Guo, Ruixia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 189
  • [26] Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis
    Lu, Ling
    Li, Yonghong
    Luo, Rong
    Xu, Junhui
    Feng, Jie
    Wang, Mingqiang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [27] PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
    Gandini, Sara
    Massi, Daniela
    Mandala, Mario
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 88 - 98
  • [28] The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis
    Paderno, Alberto
    Petrelli, Fausto
    Lorini, Luigi
    Capriotti, Vincenzo
    Gurizzan, Cristina
    Bossi, Paolo
    ORAL ONCOLOGY, 2024, 153
  • [29] PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis
    Lobrano, Renato
    Paliogiannis, Panagiotis
    Zinellu, Angelo
    Palmieri, Giuseppe
    Persico, Ivana
    Mangoni, Arduino A. A.
    Cossu, Antonio
    CURRENT ONCOLOGY, 2023, 30 (05) : 5135 - 5144
  • [30] The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis
    Xiao, Bo-Ya
    Lin, Guo-He
    Zhao, Yan-Xia
    Wang, Bi-Cheng
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (06) : 3804 - 3818